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Objective: The objective of this study was to evaluate our protocol for the identi-
fication and management of patients with immune heparin-induced thrombocyto-
penia undergoing cardiac surgery.
Methods: Among 1518 patients who underwent cardiac surgery between June 1998
and May 2001, 32 (2.1%) presented with platelet counts less than 150,000/mm3
preoperatively or a history of prolonged (3 days) intravenous exposure to heparin
or both. These 32 patients were evaluated with an enzyme-linked immunosorbent
assay for antibodies against heparin-platelet factor 4 complex. Platelets of patients
with detected antibodies were tested with the prostacyclin analog iloprost for
inhibition of heparin aggregation and determination of the inhibiting concentration
and corresponding intravenous infusion rate of iloprost. Patients with antibodies
received heparin after complete platelet inhibition with iloprost infusion. Hypoten-
sion was prevented or treated with intravenous noradrenaline. Ten randomly se-
lected patients with similar preoperative characteristics, no previous extended ex-
posure to heparin, and normal platelet counts served as controls.
Results: Ten of the 32 patients (group A, 31.3%) and none of the controls had
antibodies against heparin-platelet factor 4 complex. Patients in group A underwent
surgery with iloprost (6-24 ng · kg1 · min1) and had their blood pressure
maintained at greater than 95 mm Hg with norepinephrine infusion (1-4 g · kg1
· min1). Operative mortality was zero. There were no thrombotic complications or
bleeding requiring exploration. One patient in group A bled 1310 mL/6 hours but
did not need exploration. There was no difference in postoperative blood loss and
morbidity between groups. Platelet counts were reduced by 12.5%  8.7% (group
A) and 38.1%  15.2% (control) (P  .001) 1 hour postoperatively and reached
preoperative values by the fifth postoperative day.
Conclusions: Immune heparin-induced thrombocytopenia can be detected preoper-
atively among patients with a low platelet count or a history of prolonged heparin
exposure or both. Cardiac surgery can be safely undertaken using iloprost-induced
platelet inhibition during heparinization.
Heparin-induced thrombocytopenia and thrombosis (HITT), or he-parin-induced thrombocytopenia type II, is an immunologic dis-order that affects patients who receive prolonged (3 days)heparin anticoagulation.1-3 When heparin enters the blood, itforms a complex with platelet factor (PF) 4. Patients with HITThave been sensitized against the heparin-PF4 complex, producing
mainly immunoglobulin G antibodies against it.4 On reexposure to heparin, these
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antibodies bind to the heparin-PF4 complex at the platelet
surface receptor Fc, causing platelet activation, release of
procoagulant active microparticles and more PF4, and, con-
sequently, platelet aggregation. The newly released PF4
reacts with the circulating heparin and eventually with the
endothelial surface-attached heparin-like molecules, pro-
moting reaction with the specific antibodies.2,3 This leads to
activation of more platelets and to a vicious cycle that
causes platelet aggregation, thromboembolic complications,
and bleeding diathesis in association with thrombocytope-
nia.3,5 Patients with HITT antibodies are at high risk
(50%) for experiencing thromboembolic complications,
bleeding, and sudden death on reexposure to heparin. Death,
limb loss, myocardial infarction, coronary artery graft oc-
clusion, mesenteric infarction, deep venous thrombosis, pul-
monary embolism, stroke, intracardiac mural thrombosis,
bilateral adrenal hemorrhagic infarcts, and bleeding have
occurred intraoperatively or early postoperatively in pa-
tients with HITT receiving heparin.1,3,5-8
The management of patients with HITT antibodies who
require cardiac surgery is challenging, because heparin an-
ticoagulation is an integral part of cardiac operations per-
formed with or without extracorporeal circulation. A stan-
dard approach to these patients has not yet been established,
although several therapeutic options have been proposed on
the basis of using anticoagulants other than heparin.1,3 How-
ever, experience with the Food and Drug Administration-
approved alternative anticoagulants is limited, specific an-
tidotes are not available, and special tests not readily
available are required to monitor the effectiveness of the
alternatives.3,5,6
In an effort to prevent serious perioperative thromboem-
bolic and bleeding complications in our patients, we estab-
lished a protocol for the identification and management of
HITT-sensitive patients who need cardiac surgery with full
heparinization. The purpose of this project was 2-fold: the
preoperative recognition of patients with heparin-sensitive
antiplatelet antibodies and the prevention of platelet activa-
tion by temporary platelet function inhibition during hepa-
rinization. Our management protocol was based on reports
by Addonizio and associates,9,10 Kappa and collabora-
tors,11,12 and Palatianos and colleagues (on the use of the
prostacyclin analog iloprost [ZK 36374]).13 Addonizio and
associates9,10 and Kappa and associates11,12 reported plate-
let preservation with iloprost during cardiopulmonary by-
pass (CPB) and showed that temporary platelet inhibition
with iloprost allowed safe heparin administration in patients
with HITT undergoing cardiac or vascular operations.
Methods
Patients
From June 1998 to June 2001, 1518 patients underwent cardiac
surgery in our department. Of these patients, 32 (2.1%) were found
to have thrombocytopenia (platelet counts  150,000/mm3) or a
positive history of prolonged (3 days) exposure to heparin or
both. These 32 patients underwent the usual hemostatic assessment
and had their bleeding times tested. They were also tested for
heparin-induced platelet aggregation (HIPA) using porcine heparin
(heparin sodium, Leo Pharmaceutical Products, Ballerup, Den-
mark) after 14 days from cessation of any aspirin intake. Patients
with plasma aggregating normal donor platelets in the presence of
heparin (positive HIPA assay) were evaluated with an enzyme-
linked immunosorbent (ELISA) assay (Diagnostica Stago, Tav-
erny, France) for anti-heparin-PF4 antibodies (HITT antibod-
ies).2,4,14,15 Patients with HITT antibodies were subsequently
tested with a HIPA assay using increasing micromolar concentra-
tions of iloprost (Ilomedin, Berlex Laboratories, Edison, NJ) to
determine the dose that completely inhibited platelet aggregation
to heparin.9-12 During surgery, patients with anti-heparin-PF4 an-
tibodies were treated with iloprost to achieve complete inhibition
of HIPA before heparinization (group A or treated group). Ten
additional patients with normal platelet counts and without history
of prolonged exposure to heparin or thrombosis were matched for
age, gender, and procedure, and were included in the study as
controls (group C). Our hospital’s ethics committee approved the
use of iloprost in our patients with HITT antibodies. Each patient
signed an informed consent form.
Anesthesia Protocol
Anesthesia was induced with midazolam (0.05-0.075 mg/kg of
body weight), etomidate (0.3 mg/kg), and fentanyl (10-15 g/kg).
Neuromuscular block was induced by intravenous pancuronium or
rocuronium (0.15 mg/kg) and maintained by continuous infusion
of cisatracurium (1.5-2.0 g · kg1 · min1). Anesthesia was
maintained using sevoflurane 0.5% to 2.0% in oxygen/air and
additional boluses of fentanyl as needed or a continuous infusion
of remifentanil (0.2-1.0 g · kg1 · min1).
Each patient had a 3-lumen central venous catheter, pulmonary
artery catheter, and radial arterial catheter positioned before anes-
thesia induction. During surgery, there was continuous monitoring
of the central venous, pulmonary artery, and arterial pressures;
urinary output; electrocardiogram; and nasopharyngeal and rectal
temperatures. Tissue oxygenation was monitored with pulse oxim-
etry, and arterial blood gases were frequently tested.
Surgical Protocol and Postoperative Management
After anesthesia induction, iloprost infusion was started at 3 ng ·
kg1 · min1 intravenously and was increased progressively (dou-
bled) every 5 minutes up to the dose corresponding to the concen-
tration of iloprost, which in vitro inhibited platelet aggregation to
heparin. A HIPA test was performed 5 minutes after reaching the
target dose. Once complete inhibition of platelet aggregation to
heparin was demonstrated, the patients were given porcine heparin
for full heparinization (heparin sodium, 300 IU/kg intravenously).
Norepinephrine was infused at 0.05 g · kg1 · min1 to prevent
or treat hypotension (systolic blood pressure  100 mm Hg). For
cases requiring CPB, the activated coagulation time (ACT) was
maintained at more than 480 seconds throughout perfusion. Addi-
tional heparin was administered if needed. CPB was established
with a roller pump (Sto¨ckert-Shiley Instruments, Munich, Ger-
many), a hollow fiber membrane oxygenator (Quadrox, Jostra,
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Hirrlingen, Germany), and an arterial filter (HBF 40, Jostra) at
32°C to 33°C for cases undergoing coronary revascularization
procedures and at 28°C for valve surgery cases. Cardioprotection
was achieved with induced cardioplegic arrest. Cold (8°C) blood
cardioplegic solution was infused retrograde through the coronary
sinus and antegrade through the aortic root. Surface-heparinized
extracorporeal circuits were not used in these patients. Off-pump
procedures were performed using the Octopus 3 flexible stabiliza-
tion system (Medtronic, Inc, Minneapolis, Minn) under systemic
heparinization (heparin dose 150-200 IU/kg, ACT 350 seconds).
On termination of CPB, or after construction of the bypass grafts
for the off-pump coronary bypass cases, protamine sulfate (Leo
Pharmaceutical Products) was administered to neutralize the hep-
arin and return the ACT to normal values. The patients were
transferred to the intensive care unit (ICU), ventilated, continu-
ously monitored for arterial and pulmonary artery pressures and
electrocardiogram, and administered iloprost infusion. After dem-
onstration of the absence of circulating heparin with the Hepcon
HMS/HMS Plus blood analyzer (Medtronic, Inc), the iloprost
infusion was reduced to half and was further halved every 30
minutes until it was discontinued after the first hour in the ICU.
Iloprost was used solely for platelet inhibition according to the
protocol dose. It was not modified to treat blood pressure changes.
These conditions were treated as needed with the standard medi-
cations used in the immediate postoperative period. Blood losses
from the chest tubes were recorded every hour.
Figure 2. Effect of iloprost at various concentrations and corresponding infusion rates on HIPA in vitro. , No
iloprost; , iloprost 60 pg/mL (3 ng · kg1 · min1); Œ, 120 pg/mL (6 ng · kg1 · min1); , iloprost, 240 pg/mL (12
ng · kg1 · min1).
Figure 1. Mean blood pressure changes. Time points: 1, on arrival to the operating room; 2, iloprost infusion begins;
3, before CPB; CPB1, after start of perfusion; CPB2, middle of perfusion; CPB3, before end of perfusion; 4, after CPB;
5, first hour in ICU. Control group (solid line); iloprost-treated group (dashed line).
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Postoperative management was performed according to a stan-
dard protocol. If there was increased bleeding diathesis, red blood
cells, platelets, and fresh frozen plasma were administered as
needed to maintain the hematocrit above 26% in hemodynamically
stable patients or to correct prolonged coagulation parameters. No
heparin was administered to the patients thereafter. The intrave-
nous lines were flushed with heparin-free saline, and any need for
anticoagulation was achieved with acenocoumarin (Sintrom, No-
vartis-Pharma, Basel, Switzerland). Platelet counts were obtained
preoperatively, 1 hour after surgery, and on the first and fifth
postoperative days, and were corrected for hemodilution according
to hematocrit values.
Statistical Methods
The analysis of the data collected for the study was performed
using the following statistical methods, depending on the nature of
the data analyzed:
Longitudinal data (ie, measurements on the same variable taken
at consecutive time points for each patient) were evaluated by
repeated-measures analysis of variance (RM-ANOVA). All other
continuous variables measured at a single time point (eg, duration
of ICU stay and amounts of blood loss), aggregates of the longi-
tudinal data, and percent reduction of platelet counts from the
preoperative values were evaluated by the t test and its nonpara-
metric equivalent (Wilcoxon rank-sum test). Changes from base-
line at each time point of measurement within each group (eg, no
intergroup comparisons) were evaluated using the Student paired t
test and the Wilcoxon signed-rank test. The association between
length of perfusion and platelet count reduction was assessed with
Spearman’s correlation. In general, during the analysis, the para-
metric methods were used after testing for normality. If the test
rejected the normality assumption, then the nonparametric method
was used. The P values reported are accompanied by the type of
test they are derived from. All calculations were performed using
the SASJ statistical package (SAS Institute, Inc, Cary, NC).
Results
Ten patients were found to have HITT antibodies (0.65% of
our total patient population; 31.3% of the patients presented
with thrombocytopenia or history of prolonged heparin ther-
apy). Their preoperative bleeding times were within normal
range (6.4  1.94 minutes). Patient characteristics and
surgery data appear in Table 1. Iloprost was infused at 6 to
24 ng · kg1 · min1, achieving complete platelet inhibition
to heparin. In the control group, mean maximal blood pres-
sure decreased by 26.5 11.1 mm Hg before CPB, whereas
in the iloprost-treated group, systolic pressure decreased by
37.0  10.3 mm Hg before CPB (P  .03, Wilcoxon test).
Blood pressure was easily controlled using norepinephrine
infusion or phenylephrine boluses (Figure 1). Two patients
with high blood pressure did not require norepinephrine;
their blood pressure was readily controlled during iloprost
infusion with phenylephrine boluses (100 g). Platelet
counts were significantly reduced 1 hour after surgery in
both groups (P  .0001, RM-ANOVA). The control group
displayed a greater decrease in platelet count from baseline
at 1 hour and 1 day postoperatively than the treated group (P
 .0001 and .0487, respectively, RM-ANOVA) (Table 2).
Iloprost caused a concentration-dependent inhibition of
platelet aggregation preoperatively in vitro (Figure 2). Com-
plete inhibition of platelets occurred with iloprost infusion
at 6 to 24 ng · kg1 · min1, corresponding to plasma
concentrations of 120 to 480 pg/mL. After intravenous
iloprost administration, the HIPA test became negative at
the corresponding concentrations, as was identified in vitro
in 9 patients. In the remaining patient, the iloprost infusion
rate had to be doubled during surgery to obtain complete
platelet inhibition.
There was no operative mortality. Hematocrit values
decreased significantly in both groups over time (P .0001,
RM-ANOVA) (Table 2). There was no significant differ-
ence between groups overall or in the time progression of
the hematocrit value or at any time point measured. In the
treated group, 1 patient bled 1000 mL (1310 mL) in the
first 6 postoperative hours but did not require exploration;
he had prolonged coagulation parameters without free cir-
culating heparin (negative Hepcon test). The bleeding was
controlled with fresh frozen plasma, platelet, and red blood
cell transfusions. There was no significant difference in
mediastinal blood losses in the first 6 postoperative hours
between the treated and control groups (317.5  355.9 mL
vs 304.5  126.8 mL, respectively, P  .3634, Wilcoxon
test) and no difference in transfusion requirements (P .67,
Wilcoxon test). A patient in the treated group demonstrated
low cardiac output that required the use of an intraaortic
balloon pump for 24 hours. Mild transient jaundice ap-
peared in 1 patient in each group. In the control group, 1
patient required prolonged (48 hours) intubation, and an-
other patient required reoperation with construction of a
TABLE 1. Patient characteristics and operative data
Treated group
(n  10)
Control group
(n  10)
Female gender 1 1
Age (y) 61.1 7.2 62.7 8.4
Operation performed
CABG 7 7
MVR 3 1
CABG and MV repair 0 1
CABG and MVR 0 1
CPB time (min) 67.6 53.0 97.1 59.6
Heparin dose (IU) 16,950 5,449 22,100 9,868
Protamine dose (mg) 135.00 51.9 160.00 45.9
ACT (sec)
Baseline 133 15 130 23
During CPB 523 122 499 116
After protamine 141 20 132 11
The  values are SDs. ACT, Activated coagulation time; CABG, coronary
artery bypass grafting; CPB, cardiopulmonary bypass; MV, mitral valve;
MVR, mitral valve replacement.
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venous bypass graft because of malfunction of an internal
thoracic artery bypass graft. The lengths of postoperative
stay in the ICU and postoperative hospitalization were 1.6
 1.2 days and 6.5  1.9 days, respectively, without
significant difference between groups.
Discussion
Thrombocytopenia in patients with prior prolonged expo-
sure to heparin or with thrombotic or thromboembolic
events under heparin therapy may indicate the presence of
HITT.1-4 However, this immune disorder may be concealed,
and severe thromboembolic events may develop on heparin
administration in some patients with normal platelet
counts.4 Unfortunately, in a large proportion of patients, the
condition is recognized after the occurrence of a serious
complication. In their 14-year series, Warkentin and
Kelton1 found that approximately half of HITT-sensitive
patients were recognized only after a complicating throm-
botic event. A high index of suspicion is mandatory for
preoperative recognition of patients with HITT and preven-
tion of devastating complication(s) on heparin administra-
tion. The condition may be diagnosed by HIPA and sero-
tonin radioimmunoassay release tests or serologically by
ELISA for detection of HITT-specific antibodies against the
heparin-PF4 complex.3,4
Our protocol addresses the preoperative recognition of
HITT-sensitive patients and their intraoperative manage-
ment for prevention of activation of the HITT process. In
this protocol, HITT is diagnosed preoperatively by screen-
ing all patients who present with low platelet counts
(150,000/mm3) or a history of prolonged heparin therapy
or thrombosis regardless of platelet count. Currently, in our
practice, all our patients scheduled for surgery undergo a
preadmission complete blood count and platelet count
within the frame of a preadmission evaluation. No patient
with a low platelet count is scheduled for surgery without
prior investigation of his or her thrombocytopenia. In our
laboratory, the special diagnostic workup can be completed
within 5 to 6 hours. The determination of the iloprost
concentration that inhibits HIPA is usually performed
within 1 hour before heparinization for CPB. Therefore,
with proper mobilization of the involved services, this pro-
tocol can be applied to cases requiring urgent surgery. Since
we started using this protocol, we have not seen any of the
unexpected postoperative hard-to-manage bleeding that we
used to face sporadically. In our experience, 31.3% of
patients with thrombocytopenia who presented for cardiac
surgery tested positive for HITT antibodies. Patients testing
positive for HIPA are further tested with ELISA for HITT
antibodies. In patients with HITT antibodies, surgery is
postponed for approximately 3 months if their condition
allows it. If the antiplatelet antibodies disappear from the
patient’s plasma, surgery proceeds with standard CPB and
heparin. Any further exposure postoperatively to either un-
fractionated or low molecular weight heparin is strictly
avoided.3,5,16-18 In case the patient’s condition forbids delay
of surgery, we use iloprost for temporary platelet inhibition
(as described previously) to prevent HITT-related compli-
cations. Again, heparin is not used postoperatively in any
form. This protocol allows the safe use of heparin during
CPB in patients with HITT antibodies.
Iloprost, a stable analog of prostacyclin with a half-life of
30 minutes, is effective in completely inhibiting platelets by
binding to specific platelet receptors, activating adenyl cy-
clase, and increasing the intracellular cyclic adenosine
monophosphate levels. In addition, iloprost acts on the
arterial smooth muscle with a vasodilatory effect that may
lead to hypotension.19 At appropriate infusion rates, iloprost
allows safe heparin administration in patients with HITT
antibodies provided there is close monitoring of hemody-
namics and careful use of alpha agonists (norepinephrine
and phenylephrine) to prevent or treat hypotension.9-13 Our
data support the hypothesis that heparin may be used with
impunity in patients with HITT when their platelets are
completely inhibited with iloprost and their hemodynamics
are closely monitored. The main side effect of iloprost is
hypotension secondary to vasodilation. However, in our
experience, hypotension during iloprost infusion was
TABLE 2. Changes in hematocrit and platelet counts
Parameter Treated group Control group P value (test)
Platelet count (103/mm3)
Baseline 151.6 63.012 212.7 52.637 NS
First hour in ICU 135.7 65.488 127.7 27.949 .0001 (RM-ANOVA)
First postoperative day 114.8 49.409 136.7 40.472 .0487 (RM-ANOVA)
On discharge 165.2 65.149 198.6 96.464 NS
Hematocrit (%)
Baseline 42.28 1.99 41.01 3.52 NS
First hour in ICU 31.07 4.72 30.3 4.58 NS
First postoperative day 32.08 3.01 33.33 3.66 NS
On discharge 32.69 5.50 33.11 3.85 NS
RM-ANOVA, Repeated-measures analysis of variance; ICU, intensive care unit; NS, not significant.
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readily controlled with norepinephrine infusion (1-4 g ·
kg1 · min1) or phenylephrine boluses. In this report, we
present our first 10 patients in whom HITT antibodies were
detected preoperatively. Our overall hospital experience to
date with patients who test positive for HITT is satisfactory.
This protocol has been used successfully for the identifica-
tion and management of these patients so they can undergo
cardiac surgery without the thrombotic and hemorrhagic
complications related to their sensitivity to heparin.
Conclusion
HITT should be suspected in every patient with thrombo-
cytopenia or a positive history of prolonged heparin therapy
or thrombosis. In such patients, any heparin should be
avoided until testing for immune anti-heparin-PF4 antibod-
ies is completed. Immune HITT antibodies can be effec-
tively diagnosed preoperatively, and patients can safely
undergo cardiac surgery with temporary iloprost-induced
platelet function inhibition during heparinization and cau-
tious blood pressure control with alpha agonists.
We thank Yannis Bassiakos, PhD, for statistical analysis of the
data.
References
1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced throm-
bocytopenia. Am J Med. 1996;101:502-7.
2. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced
thrombocytopenia. N Engl J Med. 2001;344:1286-92.
3. Follis F, Schmidt CA. Cardiopulmonary bypass in patients with hep-
arin-induced thrombocytopenia and thrombosis. Ann Thorac Surg.
2000;70:2173-81.
4. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients
with heparin-induced thrombocytopenia/thrombosis are specific for
platelet factor 4 complexed with heparin or bound to endothelial cells.
J Clin Invest. 1994;93:81-8.
5. Messmore HL Jr, Wehrmacher WH. Management of heparin-induced
thrombocytopenia and postoperative bleeding in cardiovascular sur-
gery. In: Pifarre´ R, editor. Management of bleeding in cardiovascular
surgery. Philadelphia: Hanley & Belfus; 2000. p. 279-85.
6. Edmunds LH Jr. HIT, HITT, and desulfatohirudin: look before you
leap. J Thorac Cardiovasc Surg. 1995;110:1-3.
7. Aouifi A, Blanc P, Piriou V, Bastien OH, French P, Hanss M, et al.
Cardiac surgery with cardiopulmonary bypass in patients with HIT II
heparin-induced thrombocytopenia. Ann Thorac Surg. 2001;71:678-
83.
8. Burke AP, Mezzetti T, Farb A, Zech ER, Virmani R. Multiple coro-
nary artery graft occlusion in a fatal case of heparin-induced throm-
bocytopenia. Chest. 1998;114:1492-9.
9. Addonizio VP Jr, Fisher CA, Jenkin BK, Strauss JF 3rd, Musial JF,
Edmunds LH Jr. Iloprost (ZK36374), a stable analogue of prostacy-
clin, preserves platelets during simulated extracorporeal circulation.
J Thorac Cardiovasc Surg. 1985;89:926-33.
10. Addonizio VP, Fisher CA, Kappa JR, Ellison N. Prevention of hepa-
rin-induced thrombocytopenia during open heart surgery with iloprost
(ZK 36374). Surgery. 1987;102:796-807.
11. Kappa JR, Horn MK, Fisher CA, Cottrell ED, Ellison N, Addonizio
VP Jr. Efficacy of iloprost (ZK 36374) versus aspirin in preventing
heparin-induced platelet activation during cardiac operations. J Thorac
Cardiovasc Surg. 1987;94:405-13.
12. Kappa JR, Fisher CA, Todd B, Stenach N, Bell P, Campell F, et al.
Intraoperative management of patients with heparin-induced thrombo-
cytopenia. Ann Thorac Surg. 1990;49:714-23.
13. Palatianos GM, Dewanjee MK, Smith W, Novak S, Hsu LC, Kapad-
vanjwala M, et al. Platelet preservation during cardiopulmonary by-
pass with iloprost and Duraflo-II heparin-coated surfaces. ASAIO
Trans. 1991;37:620-2.
14. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced
thrombocytopenia. Blood. 1986;67:27-30.
15. Isenhart CE, Brandt JT. Platelet aggregation studies for the diagnosis
of heparin-induced thrombocytopenia. Am J Clin Pathol. 1993;99:324-
30.
16. Cummins D, Halil O, Amin S. Which patients undergoing cardiopul-
monary bypass should be assessed for development of heparin-induced
thrombocytopenia? Thromb Haemost. 1995;73:890.
17. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC,
Kelton JG. Impact of the patient population on the risk for heparin-
induced thrombocytopenia. Blood. 2000;96:1703-8.
18. Selleng S, Lubenow N, Wollert HG, Muiiejans B, Greinbacher A.
Emergency cardiopulmonary bypass in a bilaterally nephrectomized
patient with a history of heparin-induced thrombocytopenia: success-
ful reexposure to heparin. Ann Thorac Surg. 2001;71:1041-2.
19. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the
prostacyclin analogue iloprost in man. Eur J Clin Pharmacol. 1986;
30:61-8.
Discussion
Dr Michael A. Acker (Philadelphia, Pa). Your method of
prospective screening of patients at risk for HIT seems to have
identified patients at risk for thrombotic complications and death.
In your article you indicate that in elective cases the first thing one
should do is probably wait 3 months, because often the antibody
levels will decline and often disappear. This becomes a bigger
issue when you can’t wait or when the antibody levels do not
disappear.
You successfully used iloprost in 10 patients identified with
HIT, and you followed a similar successful series by Addonizio
and colleagues and Kappa and colleagues from the University of
Pennsylvania nearly 15 years ago. They found, as you did, that the
vasodilatory side effects of iloprost can be reasonably handled in
a safe fashion and that iloprost prevents platelet aggregation lead-
ing to bleeding and thrombotic complications. Unfortunately, ilo-
prost is not available in the United States.
I have 3 questions, and there are 3 slides. You did not mention
the serotonin release assay in your presentation, which is perhaps
the oldest and still the most specific and sensitive test for HIT as
far as indicating the development of thrombotic complications.
You have not used this test. Why?
We found recently that many patients who test positive for
heparin antibodies with the ELISA, test negative with the serotonin
release assay. We have successfully proceeded with CPB using a
1-time heparin dose without adjuvant or alternative means of
anticoagulation in this small group of patients. Do you believe that
patients with a negative functional assay such as serotonin or
platelet aggregation, yet a positive heparin antibody with the
ELISA, define a different group of patients who can be treated
safely in the traditional fashion?
Finally, given that iloprost is not available in the United States,
and it is interesting to conjecture why not, what is your advice for
the U.S. surgeon faced with a patient with HIT? Can you comment
on the alternative anticoagulation strategies I have listed, such as
alternative prostacyclin analogs (eg, epoprostenol), direct throm-
bin inhibitors (there are several now), defibrinating agents (eg,
ancrod and GPIIb or IIIa receptor inhibitors), or the heparinoids?
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Dr Palatianos. There is no 100% sensitive assay to identify the
patients who will have clinical HITT. We used the ELISA assay
because it was available in our hospital. Indeed, there are some
patients who test negative and may have clinical HITT, and there
are patients who test positive for antibodies and will not have
clinical HITT after heparinization for surgery. To improve diag-
nostic accuracy, we also test platelet aggregation to heparin. The
serotonin release assay is a highly sensitive method for detection
of HITT antibodies. However, it is technically demanding and not
readily available in every hospital. When available, it should be
used to identify patients prone to have HITT complications.
Patients who test positive for HITT antibodies with the ELISA
test and test negative with the serotonin release assay should be
restudied. If the ELISA assay remains positive, I think they should
be treated as HITT prone.
Although iloprost is available in Europe, its use for prevention
of HITT is not included among its accepted indications. We use it
within the frame of the clinical study. There are recent reports
promising that newer medications such as thrombin inhibitors or
heparin substitutes may become available in the near future. How-
ever, a generalized experience with them is lacking.
I think it is important to identify these patients preoperatively.
Carefully investigating the patients who come for surgery with low
platelet counts or a history of prolonged heparin therapy may help
in identifying patients with HITT antibodies. In general, we test
the occasionally seen patient with thrombocytopenia with a bleed-
ing time and perhaps with platelet aggregation studies. If these
tests are normal, we should not stop there. Some of these patients
may have HITT antibodies. With our protocol, we detected HITT
antibodies in 31.3% of these patients. Once we identify the pa-
tients, if their condition allows us to wait, postponing surgery is the
best thing to do until the antibodies clear, usually within 2 to 3
months. In case surgery cannot be postponed, the patients should
be managed with a specific protocol addressing this serious and
potentially dangerous problem.
Dr Paschalis Tossios (Cologne, Germany). We know that
these patients are sometimes very sick and that they are very
difficult to handle when the diagnosis is confirmed preoperatively.
In my own experience, heparin-induced thrombocytopenia and
associated complications occur more often postoperatively, and
they might occur with venous and arterial thromboembolic com-
plications, even with normal platelet counts. Do you have a pro-
tocol for when heparin-induced thrombocytopenia is diagnosed
during the postoperative course?
Dr Palatianos. Basically, heparin, either unfractionated or low
molecular weight, should not be given to these patients postoper-
atively, not even through a heparin flush to keep arterial or venous
lines open. Of course, HITT antibodies may be present with a
normal platelet count.
We have not observed any thrombosis in our patients. In case
of thrombosis, any heparin preparation that the patient is receiving
should be stopped, and some antithrombotic agent could be used.
Of course, the site of thrombosis, clinical picture, timing, and
general condition of the patient direct the treatment. For this
condition, prevention is the best treatment. By making the platelets
insensitive to the stimuli with iloprost, we prevent platelet activa-
tion and release reaction, aggregation, and thrombosis.
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